Effectiveness of high dose chemoradiotherapy and autologous stem cell transplantation for patients with biopsy-proven primary refractory Hodgkin's disease.
about
Hodgkin lymphoma, version 2.2015.Comparison of ICE (ifosfamide-carboplatin-etoposide) versus DHAP (cytosine arabinoside-cisplatin-dexamethasone) as salvage chemotherapy in patients with relapsed or refractory lymphoma.Different response to salvage chemotherapy but similar post-transplant outcomes in patients with relapsed and refractory Hodgkin's lymphoma.Efficacy and safety of gemcitabine, carboplatin, dexamethasone, and rituximab in patients with relapsed/refractory lymphoma: a prospective multi-center phase II study by the Puget Sound Oncology ConsortiumThe role of cytotoxic and regulatory T cells in relapsed/refractory Hodgkin lymphoma.Current status of autologous stem cell transplantation in relapsed and refractory Hodgkin's lymphomaLate relapses following high-dose autologous stem cell transplantation (HD-ASCT) for Hodgkin's lymphoma (HL) in the ABVD therapeutic eraStem cell transplantation in Hodgkin lymphoma.Managing relapsed and refractory Hodgkin lymphoma.Current role of gemcitabine in the treatment of Hodgkin lymphoma.Normalization of pre-ASCT, FDG-PET imaging with second-line, non-cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma.Allogeneic hematopoietic cell transplantation for Hodgkin lymphoma: a concise review.Comparison of Ifosfamide, Carboplatin and Etoposide versus Etoposide, Steroid, and Cytarabine Cisplatin as Salvage Chemotherapy in Patients with Refractory or Relapsed Hodgkin's lymphoma.Optimal treatment for relapsing patients with Hodgkin lymphoma.Management of relapsed and refractory classical Hodgkin lymphoma in children and adolescents.Brentuximab Vedotin (SGN-35), an antibody-drug conjugate for the treatment of CD30-positive malignancies.Hematopoietic progenitor cells transplantation for recurrent or refractory Hodgkin's lymphoma.High-dose therapy followed by stem cell transplantation in Hodgkin's lymphoma: past and future.Current role of autologous and allogeneic stem cell transplantation for relapsed and refractory hodgkin lymphoma.Primary refractory and early-relapsed Hodgkin's lymphoma: strategies for therapeutic targeting based on the tumour microenvironment.The GHSG Approach to Treating Hodgkin's Lymphoma.Microenvironment-related biomarkers and novel targets in classical Hodgkin's lymphoma.Accelerated Total Lymphoid Irradiation-containing Salvage Regimen for Patients With Refractory and Relapsed Hodgkin Lymphoma: 20 Years of Experience.Risk factors predicting outcomes for primary refractory hodgkin lymphoma patients treated with salvage chemotherapy and autologous stem cell transplantationPrognostic relevance of DHAP dose-density in relapsed Hodgkin lymphoma: an analysis of the German Hodgkin-Study Group.Current strategies for salvage treatment for relapsed classical Hodgkin lymphoma.Outcome of hematopoietic stem cell transplant as salvage therapy for Hodgkin's lymphoma in adolescents and young adults at a single institution.Brentuximab vedotin (SGN-35) in patients with transplant-naive relapsed/refractory Hodgkin lymphoma.The Gordian knot of interim 18-fluorodeoxyglucose positron emission tomography for Hodgkin lymphoma: a meta-analysis and commentary on published studies.Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe 2009.High-dose chemotherapy and autologous stem cell transplantation for Hodgkin's lymphoma in the kingdom of Saudi Arabia: King Faisal specialist hospital and research center experience.Pre-transplant 18FDG-PET predicts outcome in lymphoma patients treated with high-dose sequential chemotherapy followed by autologous stem cell transplantation.Bendamustine efficacy in Hodgkin lymphoma patients relapsed/refractory to brentuximab vedotin.Results of a phase I/II trial adding carmustine (300 mg/m2) to melphalan (200 mg/m2) in multiple myeloma patients undergoing autologous stem cell transplantation.Intensive conditioning regimen of etoposide (VP-16), cyclophosphamide and carmustine (VCB) followed by autologous hematopoietic stem cell transplantation for relapsed and refractory Hodgkin's lymphoma.IGEV regimen and a fixed dose of lenograstim: an effective mobilization regimen in pretreated Hodgkin's lymphoma patients.Risk-adapted autologous stem cell transplantation with adjuvant dexamethasone +/- thalidomide for systemic light-chain amyloidosis: results of a phase II trial.Outcome of children and adolescents with recurrent/refractory classical Hodgkin lymphoma, a study from the Société Française de Lutte contre le Cancer des Enfants et des Adolescents (SFCE).hENT1 and Hodgkin lymphoma: not just crossing the channel.Long-term outcomes after high dose therapy and autologous haematopoietic cell rescue for refractory/relapsed Hodgkin lymphoma.
P2860
Q30769157-95C4C837-2F03-4597-B030-EBBD85E57F1DQ33379431-74DBC1A6-04D1-4267-9E76-676C3411D5AEQ34095620-4F2A69D7-AA4E-4338-81AA-BEEA2DE1A0C0Q34477705-1DBB4713-89EE-4086-9D33-0703636E61F2Q35679834-125B6FFB-846C-4D64-BB00-352E9A90A1A7Q35705317-6D8FC8E7-A367-4664-A12C-7B4531FC6F8AQ35717972-70AB66DF-1309-4662-B165-28D1D3ADEB7EQ36752029-F7547D34-72FC-4131-BE50-96DCE991D991Q37086162-130DACCE-1BA4-4203-892D-A532931A876EQ37152761-1ED277E6-D6BD-40EB-B13E-CEC2947A3867Q37216194-20CE3E3F-AB6A-4138-BCD6-56A35EFAF95EQ37307724-B2CDA174-E09E-46A8-845F-ED1F08335730Q37713596-568D97C0-0D5D-48E8-A95B-AB5710534283Q37810094-A87D4638-6AD5-4071-84F2-96ED06FE95A1Q37816470-91CA67BF-4F14-42E8-8BA0-968E4BEE1BCBQ37962701-6ACB5ABE-18BD-40C3-B669-0D3600FC6A77Q38099028-525A37EC-1067-4106-9E4B-73C8C646B313Q38132819-23FDBC5F-AB05-41E0-B6BB-3616915AA25CQ38368587-A703D462-1C45-41EE-B4A0-6280062FF57BQ38466376-4D1BE7F8-6C76-4CBA-8FBC-4A41B54C8B9DQ38506223-55B2092D-966F-43DC-8371-7B5E98FC58B9Q38557033-12342C55-D965-495A-8F1E-B269621E02B6Q39195424-29133629-0C59-42BF-810B-7CCC8B4EE660Q40513698-35FA374E-6489-4018-9961-2F3035597CB5Q41029436-A62C38DD-D6E9-41FC-9BBA-2D0181570FF9Q42375641-AE74DBF6-40D5-424F-9193-53BA53EF315FQ42433067-1067BD78-9E8C-4F38-AE63-3D3A9C7CB589Q44608399-7794877D-35DD-439A-B9ED-069CF8EECF1AQ45428337-EDB1A430-A324-45CC-88E0-B16939ABF954Q45936276-C5D78B07-908C-440E-A132-DBBC6129DAF3Q46413316-AA80FC43-624C-4ECA-B159-4086B3033403Q46656078-2C7DA575-F78A-4C9C-B587-0B80975A477EQ46698290-BEA9E28B-CA40-49D4-9F2A-12E3112E919BQ46829240-765F2960-EB65-4C05-BE18-AF2F7736FE9CQ46856649-F0B52B44-6EF6-4065-AB05-2CCCFD4CCD2CQ46973779-BEBE8A02-547B-453E-A29E-2B0936624FA4Q46980729-B85E12B1-1D15-46A3-A942-CA2EE13E4448Q47424276-A88379C6-843F-402A-B2D7-91D98D842409Q47565224-FF8F2BBB-35C8-44B4-B7F7-C7A34D5DDC0CQ48389559-324E780C-67A6-4855-BD3C-6FF4B2B583FE
P2860
Effectiveness of high dose chemoradiotherapy and autologous stem cell transplantation for patients with biopsy-proven primary refractory Hodgkin's disease.
description
2004 nî lūn-bûn
@nan
2004 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի մարտին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Effectiveness of high dose che ...... refractory Hodgkin's disease.
@ast
Effectiveness of high dose che ...... refractory Hodgkin's disease.
@en
Effectiveness of high dose che ...... refractory Hodgkin's disease.
@nl
type
label
Effectiveness of high dose che ...... refractory Hodgkin's disease.
@ast
Effectiveness of high dose che ...... refractory Hodgkin's disease.
@en
Effectiveness of high dose che ...... refractory Hodgkin's disease.
@nl
prefLabel
Effectiveness of high dose che ...... refractory Hodgkin's disease.
@ast
Effectiveness of high dose che ...... refractory Hodgkin's disease.
@en
Effectiveness of high dose che ...... refractory Hodgkin's disease.
@nl
P2093
P2860
P1476
Effectiveness of high dose che ...... y refractory Hodgkin's disease
@en
P2093
Craig H Moskowitz
Joachim Yahalom
Maria Gonzalez
Stephen D Nimer
Tarun Kewalramani
P2860
P304
P356
10.1111/J.1365-2141.2003.04828.X
P407
P577
2004-03-01T00:00:00Z